Company / Operating Cash Flow per Share
BioNexus Gene Lab Corp Operating Cash Flow per Share History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow per Share
-$1.02
FY2025
5-year range
-$1.02 / $0.00
FY2021-FY2025
Trend
-763.6%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Cash Flow per Share changed -764% YoY in FY2025, a notable deviation from the 6-year average annual change of +224%.
Based on SEC 10-K filings.
-1.02 in FY2025.
Declined from $-0.13 to $-1.02 over the past 2 years.
Operating Cash Flow per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, operating cash flow per share decreased 763.6% year-over-year.
- Peak operating cash flow per share was recorded in FY2020.
Company context
Key Data Points
- Altman Z-Score 5.27 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash Flow per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$1.02 | -763.6% |
| FY2024 | -$0.12 | +5.9% |
| FY2023 | -$0.13 | -4005.6% |
| FY2022 | $0.00 | +5923.6% |
| FY2021 | $0.00 | -99.0% |
| FY2020 | $0.01 | +284.8% |
| FY2019 | -$0.00 | - |
As of FY2025 · SEC Form 10-K · Last checked Jun 21, 2026